Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Letrozole vs Hormonal Therapy in Endometrial Cancer
NCT02228681Phase 2Completed
- Sponsor
- GOG Foundation
- Start
- May 2015
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of everolimus in endometrial carcinoma (2 arms), sponsored by GOG Foundation. Primary endpoint: Frequency of Response up to 3 years. Started May 2015; status: completed.
02
Drugs
everolimus
03
Conditions
endometrial carcinoma
Beyond the preview
Go deeper on NCT02228681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02228681.